Skip to main content

Advertisement

Table 1 Baseline characteristics and microbiologic confirmation of tuberculosis in 209 HIV-1 infected and 83 HIV-1 uninfected patients receiving antituberculosis treatment

From: Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors

  HIV-1 infected (n = 209) HIV-1 uninfected (n = 83) p-value
Female, n (%) 112 (54) 25 (30) <0.001
Age in years, median (IQR) 35 (30-41) 38 (29-49) 0.035
CD4 count at TB diagnosis, n (%):    
>350 cells/mm 3 36 (17) -  
200 - 350 cells/mm 3 37 (18) -  
< 200 cells/mm 3 133 (64) -  
Not performed 3 (1) -  
Previous TB, n (%) 71 (34) 19 (23) 0.070
TB diagnosed at referral hospital, n (%): 79 (38) 13 (16) <0.001
Microbiologic confirmation at TB diagnosis 1 , n (%) 123 (59) 68 (82) <0.001
Drug susceptibilities known at TB diagnosis 1 , n (%) 67 (32) 49 (59) <0.001
Culture sent at TB diagnosis, n (%) 169 (81) 68 (82) 1.000
Extra-pulmonary TB, n (%): 82 (39) 14 (17) <0.001
Weight at TB diagnosis in kg, median (IQR) 54 (49-62) 54 (49-64) 0.644
Microbiologic confirmation at TB diagnosis and during 24 weeks of follow-up 2 , n (%) 153 (73) 70 (84) 0.048
Drug susceptibilities known at TB diagnosis and during 24 weeks of follow-up 2 , n (%) 117 (56) 57 (69) 0.296
Culture sent at TB diagnosis and/or during 24 weeks of follow-up, n (%) 190 (91) 76 (92) 1.000
  1. Key:
  2. 1 within 14 days of TB diagnosis. No TB specimens sent in 12 HIV-1 infected patients and 3 HIV-1 uninfected patients at TB diagnosis.
  3. 2 no TB specimens sent in 2 HIV-1 infected patients.
  4. TB = tuberculosis, IQR = inter-quartile range, OR = odds-ratio, 95% CI = 95% confidence interval